CollPlant Biotechnologies Ltd.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Yehiel Tal
- Full Time Employees
- 57
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Weizmann Science Park Rehovot Israel 7670104
- IPO Date
- Jan 31, 2018
- CIK
- 0001631487
- Website
- collplant.com
- Similar Companies
- Business
- CollPlant Biotechnologies Ltd. (NASDAQ: CLGN), a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs as well as medical aesthetics, develops and commercializes innovative products based on its proprietary plant-based recombinant human Type I collagen (rhCollagen) technology, which enables mass production of human-identical collagen for tissue regeneration and organ manufacturing; core offerings include rhCollagen-based BioInks such as Collink.3D 50L (powder form), Collink.3D 90 (solution for 3D bioprinting applications), and Collink.3D 50 for scalable biofabrication of tissues and organ models; regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants designed for aesthetic and post-mastectomy reconstruction with demonstrated preclinical vascularization, tissue ingrowth, and biodegradation; photocurable dermal fillers advancing toward clinical studies for skin lifting, rejuvenation, and facial contouring; VergenixSTR, a soft tissue repair matrix combined with platelet-rich plasma for tendinopathy treatment including tennis elbow, rotator cuff, and Achilles tendon injuries; and VergenixFG, a flowable gel for chronic and acute wound healing such as diabetic ulcers and surgical incisions. The company operates in the United States, Canada, Israel, Europe, and internationally, targeting markets in regenerative medicine, tissue repair, aesthetics, and biotechnology research, with approximately 57 employees. Founded in 2004 and headquartered at Weizmann Science Park in Rehovot, Israel, CollPlant maintains strategic collaborations including an expanded partnership with STEMCELL Technologies in June 2025 extending rhCollagen use to clinical development and commercial manufacturing; ongoing development agreement with AbbVie (formerly Allergan) featuring a $2 million milestone payment received in February 2025 for dermal filler progress now in clinical data review; new distribution agreements in February 2025 for VergenixSTR in Benelux, Spain, India, and Turkey; issuance of U.S. Patent No. 12,186,449 in February 2025 for photocurable dermal fillers and a Japan patent in March 2025 for rhCollagen curable BioInks; successful 3D bioprinting of commercial-size 200cc breast implants in June 2024 with refined surgical protocols and encouraging six-month preclinical results confirmed via MRI and ultrasound in early 2025; and a February 2025 cost-cutting initiative reducing workforce by 20% to extend runway into Q2 2026 while prioritizing non-dilutive financing.
COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant Issues Letter to Shareholders
Contrasting CollPlant Biotechnologies (NASDAQ:CLGN) and Inhibrx Biosciences (NASDAQ:INBX)
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement
CollPlant Biotechnologies Launches Redesigned Corporate Website
Reviewing CG Oncology (NASDAQ:CGON) and CollPlant Biotechnologies (NASDAQ:CLGN)
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS
CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler
CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex
CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS
Analyzing TuHURA Biosciences (NASDAQ:HURA) and CollPlant Biotechnologies (NASDAQ:CLGN)
CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada
CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology
First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk
CollPlant Biotechnologies Announces Positive Results from non-clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler